|Articles|December 10, 2015
Quintiles Launches Integrated Asset Development Planning
Potential assets that could benefit from this new offering include small molecule drugs, biologics, medical devices, combination therapies and novel technologies.
Advertisement
Quintiles announced the launch of its Integrated Asset Development Plan (IADP) offering. This new suite of services combines development strategy, regulatory strategy, market and patient access and commercial expertise, with in-depth therapeutic knowledge, a facilitated strategic-planning process, data analytics and modeling to deliver an integrated asset-development plan.
IADP brings together cross-functional strategies and operational delivery to enable more informed decisions that speed market access, fulfill regulatory requirements and help optimize commercial potential. Potential assets that could benefit from this new offering include small molecule drugs, biologics, medical devices, combination therapies and novel technologies.
Read the full release .
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Using AI Trial-Matching Tools to Accelerate Patient Access
September 8th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
2
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
3
ACT Brief Episode 7: Veeva and Merck Trial Efficiency, DCT Barriers, and Glucose Monitoring Strategies
4
Beyond the Algorithm: How Human-Centered AI Design Can Drive Clinical Trial Success
5